SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 17, 2006

 

Array BioPharma Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

000-31979

 

84-1460811

(State or Other

 

(Commission

 

(IRS Employer

Jurisdiction of

 

File Number)

 

Identification No.)

Incorporation)

 

 

 

 

 

 

 

 

 

3200 Walnut Street, Boulder, Colorado

 

 

 

80301

(Address of Principal Executive Offices)

 

 

 

(Zip Code)

 

Registrant’s telephone number, including area code:  (303) 381-6600

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o                                    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                                    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                                    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR

240.14d-2(b))

 

o                                    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR

240.13e-4(c))

 

 


 

ITEM 8.01. OTHER EVENTS

 

On January 17, 2006, Array issued a press release announcing that the Company has initiated dosing cancer patients in a Phase I clinical trial for its targeted small molecule anticancer drug ARRY-334543, the full text of which is attached hereto as Exhibit 99.1.

 

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

 

(c) Exhibits.

 

99.1                           Press release dated January 17, 2006 entitled “Array BioPharma Initiates Phase I Clinical Trial for Targeted Anticancer Drug ARRY-334543.”

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ARRAY BIOPHARMA INC.

 

 

 

 

 

 

Date: January 17, 2006

By:

 /s/ Robert E. Conway

 

 

 Robert E. Conway

 

 

 Chief Executive Officer

 


 

EXHIBIT INDEX

 

Exhibit No.

 

 

 

 

 

99.1

 

Press release dated January 17, 2006 entitled “Array BioPharma Initiates Phase I Clinical Trial for Targeted Anticancer Drug ARRY-334543.”